Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc. (ticker symbol not specified in the cover page provided) is a clinical-stage radiopharmaceutical development company pioneering advanced cancer treatments through targeted alpha therapies. The company's core technology leverages the alpha-emitting isotope Lead-212 to deliver powerful… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Perspective Therapeutics, Inc. does
In the company’s own words
Perspective Therapeutics, Inc. (ticker symbol not specified in the cover page provided) is a clinical-stage radiopharmaceutical development company pioneering advanced cancer treatments through targeted alpha therapies. The company's core technology leverages the alpha-emitting isotope Lead-212 to deliver powerful radiation directly to cancer cells while minimizing damage to healthy tissue. This approach is complemented by imaging diagnostics using Lead-203, creating a theranostic platform that enables personalized treatment and optimized patient outcomes.
The company operates through three primary wholly-owned subsidiaries: Viewpoint Molecular Targeting, Inc. and Isoray Medical, Inc., alongside its main operating entity. Perspective's pipeline includes three lead programs currently in Phase 1/2a clinical trials in the United States. VMT-α-NET targets neuroendocrine tumors expressing somatostatin receptor type 2, VMT01 addresses melanoma tumors expressing melanocortin 1 receptor, and PSV359 targets solid tumors expressing fibroblast activation protein.
Perspective's competitive advantages stem from its proprietary targeted alpha therapy platform developed over fifteen years at the University of Iowa, combined with deep expertise in Lead-212 chemistry and biology. The company has developed specialized chelator technology and targeting peptides that enable selective tumor localization while promoting rapid clearance of non-targeted compounds. This differentiation addresses a longstanding challenge in radiopharmaceutical development regarding balancing efficacy with safety.
The company has received Fast Track designation from the FDA for VMT-α-NET and VMT01, accelerating potential regulatory pathways. In January 2024, Perspective entered a strategic agreement with an affiliate of Lantheus Holdings, Inc., receiving a $28 million upfront payment in exchange for an exclusive option to negotiate licensing rights to VMT-α-NET and co-funding rights for early-stage PSMA and GRPR-targeting candidates.
Perspective's manufacturing strategy emphasizes building a regional network of drug product finishing facilities enabled by proprietary Lead-212 generator technologies, designed to support both clinical trials and future commercial operations. The company retains global development and commercialization rights to all current product candidates and operates as a smaller reporting company within the biopharmaceutical industry focused on precision oncology.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- SEATTLE, WA
- Fiscal year end
- December
- CIK
- 728387
- SIC
- 2834
Financial performance, year by year
Fiscal 2014–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Perspective Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Perspective Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Perspective Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Perspective Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Perspective Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”